Cogent Biosciences, Inc. Expected to Earn FY2026 Earnings of ($0.10) Per Share (NASDAQ:COGT)

Cogent Biosciences, Inc. (NASDAQ:COGTGet Rating) – Analysts at Wedbush issued their FY2026 EPS estimates for Cogent Biosciences in a note issued to investors on Tuesday, May 10th. Wedbush analyst D. Nierengarten anticipates that the technology company will post earnings per share of ($0.10) for the year.

Separately, Zacks Investment Research raised shares of Cogent Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th.

NASDAQ:COGT opened at $4.22 on Thursday. Cogent Biosciences has a 12 month low of $4.12 and a 12 month high of $11.06. The company has a 50 day simple moving average of $7.12 and a two-hundred day simple moving average of $7.69. The company has a market cap of $193.36 million, a PE ratio of -2.27 and a beta of 2.86.

Cogent Biosciences (NASDAQ:COGTGet Rating) last posted its earnings results on Tuesday, May 10th. The technology company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.16).

Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its stake in shares of Cogent Biosciences by 50.4% during the 3rd quarter. Royal Bank of Canada now owns 3,827 shares of the technology company’s stock valued at $32,000 after buying an additional 1,283 shares in the last quarter. Metropolitan Life Insurance Co NY purchased a new position in shares of Cogent Biosciences during the 3rd quarter valued at $89,000. Squarepoint Ops LLC purchased a new position in shares of Cogent Biosciences during the 4th quarter valued at $90,000. Trexquant Investment LP purchased a new position in shares of Cogent Biosciences during the 3rd quarter valued at $96,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Cogent Biosciences during the 3rd quarter valued at $109,000.

About Cogent Biosciences (Get Rating)

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

Recommended Stories

Earnings History and Estimates for Cogent Biosciences (NASDAQ:COGT)

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.